Harrow Health (HROW) Stock Analysis & AI Equity Report

Drug Manufacturers - Specialty & Generic USD Explore free reports

Harrow Health (HROW) overview

Harrow Health (HROW) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 272m and operating profit of USD 30.5m; the year-end share price was 49.00 USD and market capitalisation was USD 1,824m. Harrow Health is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Harrow Health's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 52.4mFY 2025
Share price49.00 USDFY 2025 year end
RevenueUSD 272mFY 2025
Operating profitUSD 30.5mFY 2025
Net earningsUSD -5.1mFY 2025
Market capitalisationUSD 1,824mFY 2025 year end

About Harrow Health

Harrow develops and supplies ophthalmic medications for eye care professionals and patients in the United States and Canada. Its portfolio includes branded prescription treatments for conditions such as dry eye, cataracts, glaucoma, allergic conjunctivitis, and retinal disease, as well as nonprescription lubricant eye drops. The company markets and sells products including eye drops, gels, suspensions, and injectable medicines.

Generate the Harrow Health report

Harrow Health is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Harrow Health and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Harrow Health

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.